Why the study?
Does lipid-lowering therapy prevent coronary heart disease in patients with type 2 diabetes?
Does lipid-lowering therapy prevent coronary heart disease in patients with type 2 diabetes?
This review highlights the need for and ongoing status of lipid-lowering trials specifically targeting patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Evidence gap persists for lipid-lowering in type 2 diabetes; leaves open whether dedicated trials will confirm benefit.
The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.
No takes yet. Share an insight, caveat, or question.
Betteridge et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: